The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Trump Administration to Appeal Ruling Blocking Price Disclosure for Drug Ads

Trump Administration to Appeal Ruling Blocking Price Disclosure for Drug Ads

August 21, 2019 • By Carl O'Donnell

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—The Trump administration is appealing a court ruling that struck down its plan to compel pharmaceutical companies to disclose wholesale prices of their drugs in televisions advertisements.

You Might Also Like
  • Trump Says Drug Companies to Announce “Massive” Price Cuts Soon
  • Trump Seeks to Base Medicare Drug Prices on Lower Overseas Rates
  • Trump Administration Proposes Medicare Rules Aimed at Opioids, Drug Costs
Explore This Issue
April 2008

The U.S. Department of Health and Human Services (HHS) filed a notice of appeal on Wednesday, as it prepares to challenge the July federal court ruling.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“If the drug companies are embarrassed by their prices or afraid that the prices will scare patients away, they should lower them,” said Caitlin Oakley, a spokeswoman for HHS.

In his ruling, U.S. District Judge Amit Mehta in Washington said that HHS lacked the authority from U.S. Congress to compel drug manufacturers to disclose list prices.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The administration issued the rule in May.

The rule, which applied to drugs with list prices exceeding $35 for a one-month supply, is part of a broader push by President Donald Trump to lower drug prices.

HHS said in July that it and the U.S. Food and Drug Administration will propose a rule that will allow it to authorize states and other groups to pursue pilot projects related to importing drugs from Canada.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Reuters has previously reported that the administration is considering broadening its plans to link the cost of some drugs for the government Medicare program to an international pricing index.

Reporting by Carl O’Donnell Editing by Sonya Hepinstall

Filed Under: Drug Updates Tagged With: Advertising, drug cost, drug prices, television advertisements, Trump administrationIssue: April 2008

You Might Also Like:
  • Trump Says Drug Companies to Announce “Massive” Price Cuts Soon
  • Trump Seeks to Base Medicare Drug Prices on Lower Overseas Rates
  • Trump Administration Proposes Medicare Rules Aimed at Opioids, Drug Costs
  • U.S. to Require Drugmakers to Show Prices in TV Ads

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)